Atea Pharmaceuticals, Inc. (AVIR) — Financial statements
Income statement, balance sheet, and cash flow for Atea Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 351 | |
| Cost of Revenue | 0.00↓100.0% | 83↑18.9% | 70↑12.3% | 62↓62.7% | 167 | |
| Gross Profit | 0.00↑100.0% | -83↓18.9% | -70↓12.3% | -62↓133.9% | 184 | |
| Operating Expenses | ||||||
| R&D Expenses | 148↑1.8% | 145↑9.5% | 133↑49.5% | 89↓46.9% | 167 | |
| General & Administrative Expenses | 33↓32.7% | 49↓2.1% | 50↑2.5% | 49↑6.4% | 46 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 33↓32.7% | 49↓2.1% | 50↑2.5% | 49↑6.4% | 46 | |
| Other Expenses | 0.00↑100.0% | -85↑4.5% | -89↓28.0% | -69↑58.6% | -167 | |
| Operating Expenses | 181↑65.1% | 110↑16.5% | 94↑37.8% | 68↑49.1% | 46 | |
| Total Costs & Expenses | 181↓6.3% | 193↑17.5% | 164↑25.7% | 131↓38.7% | 213 | |
| Operating Results | ||||||
| Operating Income | -181↑6.3% | -193↓17.5% | -164↓25.7% | -131↓194.4% | 138 | |
| Depreciation & Amortization | 0.42↑0.0% | 0.42↑0.0% | 0.42↑60.0% | 0.26↑796.6% | 0.03 | |
| EBITDA | -180↓36.9% | -132↓10.2% | -120↓7.9% | -111↓180.1% | 138 | |
| EBIT | -181↓36.8% | -132↓10.2% | -120↓8.0% | -111↓180.3% | 138 | |
| Interest & Other Income | ||||||
| Net Interest Income | 16↓35.8% | 25↓12.8% | 29 | 0.00↓100.0% | 0.21 | |
| Interest Income | 16↓35.8% | 25↓12.8% | 29↑162.1% | 11↑5135.2% | 0.21 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 11 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -61↓37.6% | -44↓125.9% | -20 | 0.00 | |
| Other Income / Expenses | 16↓35.8% | 25↓12.8% | 29↑162.1% | 11↑5135.2% | 0.21 | |
| Income Before Tax | -165↑1.8% | -167↓24.1% | -135↓12.9% | -119↓186.2% | 139 | |
| Income Tax Expense | -6↓766.2% | 0.93↓9.1% | 1↑128.4% | -4↓120.6% | 17 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -158↑6.0% | -168↓23.9% | -136↓17.3% | -116↓195.6% | 121 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -158↑6.0% | -168↓23.9% | -136↓17.3% | -116↓195.6% | 121 | |
| Bottom-Line Net Income | -158↑6.0% | -168↓23.9% | -136↓17.3% | -116↓195.6% | 121 | |
| EPS (Basic) | -1.94↑3.0% | -2.00↓22.7% | -1.63↓17.3% | -1.39↓195.2% | 1.46 | |
| EPS (Diluted) | -1.94↑3.0% | -2.00↓22.7% | -1.63↓17.3% | -1.39↓201.5% | 1.37 | |
| Weighted Average Shares | 81↓3.3% | 84↑1.0% | 83↑0.2% | 83↑0.5% | 83 | |
| Weighted Average Diluted Shares | 81↓3.3% | 84↑1.0% | 83↑0.2% | 83↓5.7% | 88 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.